These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
472 related articles for article (PubMed ID: 23979365)
1. A randomized, double-blind, placebo-controlled, Phase 2b study to evaluate the safety and efficacy of recombinant human soluble thrombomodulin, ART-123, in patients with sepsis and suspected disseminated intravascular coagulation. Vincent JL; Ramesh MK; Ernest D; LaRosa SP; Pachl J; Aikawa N; Hoste E; Levy H; Hirman J; Levi M; Daga M; Kutsogiannis DJ; Crowther M; Bernard GR; Devriendt J; Puigserver JV; Blanzaco DU; Esmon CT; Parrillo JE; Guzzi L; Henderson SJ; Pothirat C; Mehta P; Fareed J; Talwar D; Tsuruta K; Gorelick KJ; Osawa Y; Kaul I Crit Care Med; 2013 Sep; 41(9):2069-79. PubMed ID: 23979365 [TBL] [Abstract][Full Text] [Related]
2. Effect of a Recombinant Human Soluble Thrombomodulin on Baseline Coagulation Biomarker Levels and Mortality Outcome in Patients With Sepsis-Associated Coagulopathy. Levi M; Vincent JL; Tanaka K; Radford AH; Kayanoki T; Fineberg DA; Hoppensteadt D; Fareed J Crit Care Med; 2020 Aug; 48(8):1140-1147. PubMed ID: 32697484 [TBL] [Abstract][Full Text] [Related]
3. Benefit profile of recombinant human soluble thrombomodulin in sepsis-induced disseminated intravascular coagulation: a multicenter propensity score analysis. Yoshimura J; Yamakawa K; Ogura H; Umemura Y; Takahashi H; Morikawa M; Inoue Y; Fujimi S; Tanaka H; Hamasaki T; Shimazu T Crit Care; 2015 Mar; 19(1):78. PubMed ID: 25883031 [TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial. Saito H; Maruyama I; Shimazaki S; Yamamoto Y; Aikawa N; Ohno R; Hirayama A; Matsuda T; Asakura H; Nakashima M; Aoki N J Thromb Haemost; 2007 Jan; 5(1):31-41. PubMed ID: 17059423 [TBL] [Abstract][Full Text] [Related]
5. Thrombin generation mediators and markers in sepsis-associated coagulopathy and their modulation by recombinant thrombomodulin. Hoppensteadt D; Tsuruta K; Cunanan J; Hirman J; Kaul I; Osawa Y; Fareed J Clin Appl Thromb Hemost; 2014 Mar; 20(2):129-35. PubMed ID: 23804232 [TBL] [Abstract][Full Text] [Related]
6. Recombinant human soluble thrombomodulin in sepsis-induced disseminated intravascular coagulation: a multicenter propensity score analysis. Yamakawa K; Ogura H; Fujimi S; Morikawa M; Ogawa Y; Mohri T; Nakamori Y; Inoue Y; Kuwagata Y; Tanaka H; Hamasaki T; Shimazu T Intensive Care Med; 2013 Apr; 39(4):644-52. PubMed ID: 23361628 [TBL] [Abstract][Full Text] [Related]
7. Recombinant human soluble thrombomodulin and mortality in sepsis-induced disseminated intravascular coagulation. A multicentre retrospective study. Hayakawa M; Yamakawa K; Saito S; Uchino S; Kudo D; Iizuka Y; Sanui M; Takimoto K; Mayumi T; Ono K; Thromb Haemost; 2016 Jun; 115(6):1157-66. PubMed ID: 26939575 [TBL] [Abstract][Full Text] [Related]
8. Effect of a Recombinant Human Soluble Thrombomodulin on Mortality in Patients With Sepsis-Associated Coagulopathy: The SCARLET Randomized Clinical Trial. Vincent JL; Francois B; Zabolotskikh I; Daga MK; Lascarrou JB; Kirov MY; Pettilä V; Wittebole X; Meziani F; Mercier E; Lobo SM; Barie PS; Crowther M; Esmon CT; Fareed J; Gando S; Gorelick KJ; Levi M; Mira JP; Opal SM; Parrillo J; Russell JA; Saito H; Tsuruta K; Sakai T; Fineberg D; JAMA; 2019 May; 321(20):1993-2002. PubMed ID: 31104069 [TBL] [Abstract][Full Text] [Related]
9. The efficacy and safety of antithrombin and recombinant human thrombomodulin combination therapy in patients with severe sepsis and disseminated intravascular coagulation. Yasuda N; Goto K; Ohchi Y; Abe T; Koga H; Kitano T J Crit Care; 2016 Dec; 36():29-34. PubMed ID: 27546744 [TBL] [Abstract][Full Text] [Related]
10. Multicenter clinical experience with recombinant soluble thrombomodulin for disseminated intravascular coagulation associated with severe acute cholecystitis. Ogura T; Eguchi T; Amano M; Sano T; Nishioka N; Miyano A; Tsujimae M; Tanimura H; Yamada T; Terashima Y; Okada A; Higuchi K Thromb Res; 2019 Apr; 176():74-78. PubMed ID: 30780007 [TBL] [Abstract][Full Text] [Related]
11. Interleukin-1 Receptor Blockade Is Associated With Reduced Mortality in Sepsis Patients With Features of Macrophage Activation Syndrome: Reanalysis of a Prior Phase III Trial. Shakoory B; Carcillo JA; Chatham WW; Amdur RL; Zhao H; Dinarello CA; Cron RQ; Opal SM Crit Care Med; 2016 Feb; 44(2):275-81. PubMed ID: 26584195 [TBL] [Abstract][Full Text] [Related]
12. Treatment effects of recombinant human soluble thrombomodulin in patients with severe sepsis: a historical control study. Yamakawa K; Fujimi S; Mohri T; Matsuda H; Nakamori Y; Hirose T; Tasaki O; Ogura H; Kuwagata Y; Hamasaki T; Shimazu T Crit Care; 2011; 15(3):R123. PubMed ID: 21569368 [TBL] [Abstract][Full Text] [Related]
13. Effect of Recombinant Human Soluble Thrombomodulin on Coagulation-Related Variables in Patients With Sepsis-Induced Disseminated Intravascular Coagulation: A Retrospective Observational Study. Mitaka C; Kawagoe I; Satoh D; Hayashida M Clin Appl Thromb Hemost; 2021; 27():10760296211050356. PubMed ID: 34859680 [TBL] [Abstract][Full Text] [Related]
14. Thrombomodulin in disseminated intravascular coagulation and other critical conditions-a multi-faceted anticoagulant protein with therapeutic potential. Ito T; Thachil J; Asakura H; Levy JH; Iba T Crit Care; 2019 Aug; 23(1):280. PubMed ID: 31416465 [TBL] [Abstract][Full Text] [Related]
15. Serum thrombomodulin level relates to the clinical course of disseminated intravascular coagulation, multiorgan dysfunction syndrome, and mortality in patients with sepsis. Lin SM; Wang YM; Lin HC; Lee KY; Huang CD; Liu CY; Wang CH; Kuo HP Crit Care Med; 2008 Mar; 36(3):683-9. PubMed ID: 18431261 [TBL] [Abstract][Full Text] [Related]
16. The efficacy of recombinant human soluble thrombomodulin for obstetric disseminated intravascular coagulation: a retrospective study. Yoshihara M; Uno K; Tano S; Mayama M; Ukai M; Kondo S; Kokabu T; Kishigami Y; Oguchi H Crit Care; 2015 Oct; 19():369. PubMed ID: 26481315 [TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of recombinant human soluble thrombomodulin in patients with sepsis-induced disseminated intravascular coagulation - A meta-analysis. Kato H; Hagihara M; Asai N; Umemura T; Hirai J; Mori N; Yamagishi Y; Iwamoto T; Mikamo H Thromb Res; 2023 Jun; 226():165-172. PubMed ID: 37182388 [TBL] [Abstract][Full Text] [Related]
18. A retrospective comparative study of recombinant human thrombomodulin and gabexate mesilate in sepsis-induced disseminated intravascular coagulation patients. Takazono T; Nakamura S; Imamura Y; Yoshioka S; Miyazaki T; Izumikawa K; Sawai T; Matsuo N; Yanagihara K; Suyama N; Kohno S J Infect Chemother; 2014 Aug; 20(8):484-8. PubMed ID: 24855912 [TBL] [Abstract][Full Text] [Related]
19. Comparison of recombinant human thrombomodulin and gabexate mesylate for treatment of disseminated intravascular coagulation (DIC) with sepsis following emergent gastrointestinal surgery: a retrospective study. Akahoshi T; Sugimori H; Kaku N; Tokuda K; Nagata T; Noda E; Morita M; Hashizume M; Maehara Y Eur J Trauma Emerg Surg; 2015 Oct; 41(5):531-8. PubMed ID: 26038004 [TBL] [Abstract][Full Text] [Related]
20. Can recombinant human thrombomodulin increase survival among patients with severe septic-induced disseminated intravascular coagulation: a single-centre, open-label, randomised controlled trial. Hagiwara A; Tanaka N; Uemura T; Matsuda W; Kimura A BMJ Open; 2016 Dec; 6(12):e012850. PubMed ID: 28039291 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]